A comparative study of oral zinc sulfate as a treatment for visceral leishmaniasis in Iraq
العناوين الأخرى
دراسة سريرية مقارنة لكبريتات الزنك المعطاة عن طريق الفم كعلاج لللايشمانيا الحشوية في العراق
المصدر
Journal of the Arab Board of Health Specializations
العدد
المجلد 5، العدد 3 (31 أغسطس/آب 2003)، ص ص. 9-17، 9ص.
الناشر
المجلس العربي للاختصاصات الصحية
تاريخ النشر
2003-08-31
دولة النشر
سوريا
عدد الصفحات
9
التخصصات الرئيسية
الملخص AR
Objectives : To our knowledge, this is the first comparative clinical study to determine the efficacy of oral zinc sulfate as a new therapy for visceral leishmaniasis (VL).
Methods: Eighty-one cases of VL diagnosed clinically and confirmed by serologic and/or histopathological tests fulfilled the required period of drug employment (1-3 wks).
They were randomly assigned to receive either parenteral sodium stibogluconate (SSG) in its recommended dose or oral zinc sulfate (20 mg/kg/day up to 200 mg/day divided into 3 equal doses).
Both specific and non-specific signs of (VL) infection were recorded initially and followed up weekly.
Patients were monitored for the drug side effects.
Results : Zinc sulfate-induced improvement in fever, organomegaly, and weight loss was comparable (p>0.05) to that induced by SSG.
Such improvement was consistent in all therapy subgroups, i.e., whether for 1, 2, or 3 weeks; moreover, splenomegaly improved more (0.01
Based on the overall response of each patient individually, the following results were obtained.
One-week therapy: 16/20 (80%) patients apparently responded to zinc sulfate vs.
13/22 (59%) of patients who received SSG.
Two-week therapy: 10/12 (83.3%) patients apparently responded to zinc sulfate vs.
8/14 (57.1%) patients who received SSG.
Three-week therapy: 6/6 (100%) patients were cured clinically in the zinc sulfate group vs.
6/7(85.7%) patients who received SSG.
Conclusion: Oral zinc sulfate (20mg/kg/day up to 200 mg/day as a maximum divided into 3 equal doses for 3 weeks) represents a promising, effective, tolerable, safe, and new treatment for VL in Iraq.
الملخص EN
Objectives : To our knowledge, this is the first comparative clinical study to determine the efficacy of oral zinc sulfate as a new therapy for visceral leishmaniasis (VL).
Methods: Eighty-one cases of VL diagnosed clinically and confirmed by serologic and/or histopathological tests fulfilled the required period of drug employment (1-3 wks).
They were randomly assigned to receive either parenteral sodium stibogluconate (SSG) in its recommended dose or oral zinc sulfate (20 mg/kg/day up to 200 mg/day divided into 3 equal doses).
Both specific and non-specific signs of (VL) infection were recorded initially and followed up weekly.
Patients were monitored for the drug side effects.
Results : Zinc sulfate-induced improvement in fever, organomegaly, and weight loss was comparable (p>0.05) to that induced by SSG.
Such improvement was consistent in all therapy subgroups, i.e., whether for 1, 2, or 3 weeks; moreover, splenomegaly improved more (0.01
Based on the overall response of each patient individually, the following results were obtained.
One-week therapy: 16/20 (80%) patients apparently responded to zinc sulfate vs.
13/22 (59%) of patients who received SSG.
Two-week therapy: 10/12 (83.3%) patients apparently responded to zinc sulfate vs.
8/14 (57.1%) patients who received SSG.
Three-week therapy: 6/6 (100%) patients were cured clinically in the zinc sulfate group vs.
6/7(85.7%) patients who received SSG.
Conclusion: Oral zinc sulfate (20mg/kg/day up to 200 mg/day as a maximum divided into 3 equal doses for 3 weeks) represents a promising, effective, tolerable, safe, and new treatment for VL in Iraq.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Zubaydi, Adib Ahmad Kazim& al-Jawad, Faruq Hasan& al-Ruznamaji, Najm. 2003. A comparative study of oral zinc sulfate as a treatment for visceral leishmaniasis in Iraq. Journal of the Arab Board of Health Specializations،Vol. 5, no. 3, pp.9-17.
https://search.emarefa.net/detail/BIM-146440
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Zubaydi, Adib Ahmad Kazim…[et al.]. A comparative study of oral zinc sulfate as a treatment for visceral leishmaniasis in Iraq. Journal of the Arab Board of Health Specializations Vol. 5, no. 3(August 2003), pp.9-17.
https://search.emarefa.net/detail/BIM-146440
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Zubaydi, Adib Ahmad Kazim& al-Jawad, Faruq Hasan& al-Ruznamaji, Najm. A comparative study of oral zinc sulfate as a treatment for visceral leishmaniasis in Iraq. Journal of the Arab Board of Health Specializations. 2003. Vol. 5, no. 3, pp.9-17.
https://search.emarefa.net/detail/BIM-146440
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 16-17
رقم السجل
BIM-146440
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر